Pfizer (PFE)
International Stocks
Buy
The speaker evaluates Pfizer's dividend yield and developments in its product pipeline.
Jim Cramer33d
* Does not constitute investment advice
Yükleniyor...
Yükleniyor...
How recommendation distribution changed over time
Covered by 5 analysts
Significant disagreement among analysts
Last evaluation 33+ days ago - stale data
Both buy and sell recommendations exist
Decreasing interest recently
Chronological view of analyst recommendations for this asset
The speaker evaluates Pfizer's dividend yield and developments in its product pipeline.
CNBC TelevisionThe speaker analyzes capital costs in the biotech sector and competition in the global vaccine market.
CNBC TelevisionThe speaker evaluates Pfizer's long-term growth strategy, focusing on its strong product portfolio in obesity drugs and oncology. They analyze the company's growth in non-COVID business, new product catalysts in its pipeline, and dividend policy.
Yahoo FinanceThe CEO evaluates the company's clinical trials for the obesity market and the sustainability of the dividend policy despite patent expirations.
CNBC TelevisionThe speaker evaluates the company's investments in obesity drugs and its clinical stages.
CNBC TelevisionThe speaker examines the situation of the company's current platform and potential expansion strategies in light of CDC recommendations.
CNBC TelevisionThe analyst interprets the market positioning and future strategies of major pharmaceutical firms as regulatory uncertainties in the sector diminish.
CNBC TelevisionThe speaker examines the potential effects on company margins of the government making agreements to lower drug prices through coercive methods.
CNBC-eDr. Scott Gottlieb evaluates the legal implications for pharmaceutical manufacturers regarding the vaccine schedule changes proposed by HHS Secretary RFK Jr. He analyzes the potential removal of the liability shield under the Vaccine Injury Compensation Program and the risk of exposing manufacturers to direct litigation.
CNBC TelevisionThe speaker comments on the lack of momentum in the stock despite the high dividend yield and recent developments.
CNBC TelevisionThe speaker evaluates the company as a weak hold due to lack of momentum and dissatisfaction with recent updates, despite its good yield.
CNBC TelevisionThe speaker analyzes the selling pressure arising from the 2026 revenue guidance falling below consensus and risks related to loss of exclusivity.
Yahoo FinanceThe speaker analyzes the 'renaissance' period in the biotechnology sector, companies' cash flow visibility, and increasing merger/acquisition (M&A) activities.
CNBC TelevisionThe host examines the company's tight cash flow and growth risks despite its high dividend yield.
Yahoo FinanceThe speaker evaluates Pfizer's dividend yield and developments in its product pipeline.
* Does not constitute investment advice
The speaker analyzes capital costs in the biotech sector and competition in the global vaccine market.
* Does not constitute investment advice
The speaker evaluates Pfizer's long-term growth strategy, focusing on its strong product portfolio in obesity drugs and oncology. They analyze the company's growth in non-COVID business, new product catalysts in its pipeline, and dividend policy.
* Does not constitute investment advice
The CEO evaluates the company's clinical trials for the obesity market and the sustainability of the dividend policy despite patent expirations.
* Does not constitute investment advice
The speaker evaluates the company's investments in obesity drugs and its clinical stages.
* Does not constitute investment advice
The speaker examines the situation of the company's current platform and potential expansion strategies in light of CDC recommendations.
* Does not constitute investment advice
The analyst interprets the market positioning and future strategies of major pharmaceutical firms as regulatory uncertainties in the sector diminish.
* Does not constitute investment advice
The speaker examines the potential effects on company margins of the government making agreements to lower drug prices through coercive methods.
* Does not constitute investment advice
Dr. Scott Gottlieb evaluates the legal implications for pharmaceutical manufacturers regarding the vaccine schedule changes proposed by HHS Secretary RFK Jr. He analyzes the potential removal of the liability shield under the Vaccine Injury Compensation Program and the risk of exposing manufacturers to direct litigation.
* Does not constitute investment advice
The speaker comments on the lack of momentum in the stock despite the high dividend yield and recent developments.
* Does not constitute investment advice
The speaker evaluates the company as a weak hold due to lack of momentum and dissatisfaction with recent updates, despite its good yield.
* Does not constitute investment advice
The speaker analyzes the selling pressure arising from the 2026 revenue guidance falling below consensus and risks related to loss of exclusivity.
* Does not constitute investment advice
The speaker analyzes the 'renaissance' period in the biotechnology sector, companies' cash flow visibility, and increasing merger/acquisition (M&A) activities.
* Does not constitute investment advice
The speaker evaluates the company's dividend yield and future plans.
* Does not constitute investment advice
The host examines the company's tight cash flow and growth risks despite its high dividend yield.
* Does not constitute investment advice